The OBR Video Center Features educational videos covering a wide range of oncology specific topics.
Dr. Shroff, Medical Director, Clinical Trials Office, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, discusses the most promising pathways for targeted therapies in hepatobiliary and esophagogastric cancers
Tags: ASCO GI Conference CoverageEsophagealLiver (includes HCC, Billiary Tract)
Published: 15 January 2021
Andrew X. Zhu, MD, PhD, discusses the final results of the ClarIDHy trial from ASCO GI 2021
Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, ...
Andrew X. Zhu, MD, PhD, speculates on the potential impact of the ClarIDHy trial
Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, ...
Andrew X. Zhu, MD, PhD, elaborates on the role of genetic testing in cholangiocarcinoma
Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, ...
Andrew X. Zhu, MD, PhD, on ivosidenib as a 1st line therapy for patients with CCA & an IDH1 mutation
Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, ...
Thomas J. George, MD, regarding the NRG-GI002 trial as presented at ASCO GI 2021
Dr. George, Director, GI Oncology Program, University of Florida, discusses primary results from the NRG-GI002 trial as presented at the ...
Zev Wainberg, MD, elaborates on outcomes from the FIGHT trial as presented at ASCO GI 2021
Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology ...
Thomas J. George, MD, elaborates on the design of the NRG-GI002 clinical trial
Dr. George, Director, GI Oncology Program, University of Florida, elaborates on the design of the NRG-GI002 clinical trial
Zev Wainberg, MD, discusses the safety profile of bemarituzumab
Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology ...
Thomas J. George, MD, considers results from the experimental arms of the NRG-GI002 clinical trial
Dr. George, Director, GI Oncology Program, University of Florida, considers results from the experimental arms of the NRG-GI002 clinical trial
Zev Wainberg, MD, speculates on the role of bemarituzumab in other FGFR2b-positive tumor types
Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology ...
Follow @OBRTweets